Comparative Pharmacology
Head-to-head clinical analysis: NASACORT versus NASONEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NASACORT versus NASONEX.
NASACORT vs NASONEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triamcinolone acetonide, a corticosteroid, exerts anti-inflammatory effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production, thereby decreasing nasal inflammation.
Corticosteroid with anti-inflammatory activity; binds to glucocorticoid receptors, inhibiting inflammatory mediators like prostaglandins and leukotrienes.
110 mcg (2 sprays) per nostril once daily; maximum: 440 mcg (4 sprays) per nostril once daily. Intranasal administration.
Mometasone furoate 200 mcg per day as 2 sprays (50 mcg/spray) in each nostril once daily. May reduce to 100 mcg per day (1 spray per nostril once daily) if symptoms controlled. Maximum 200 mcg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours after intranasal administration; however, due to prolonged residence time in nasal mucosa, clinical effects persist beyond plasma half-life.
The terminal elimination half-life of mometasone furoate following intranasal administration is approximately 5.8 hours (range 2.7–11.5 hours) in adults, reflecting rapid clearance from systemic circulation.
Primarily hepatic metabolism via CYP3A4; renal excretion accounts for <5% of unchanged drug; biliary/fecal excretion of metabolites accounts for ~60% of total clearance.
Mometasone furoate is extensively metabolized in the liver, primarily via CYP3A4, and metabolites are excreted mostly in feces (approximately 74%) and to a lesser extent in urine (approximately 8%).
Category C
Category C
Intranasal Corticosteroid
Intranasal Corticosteroid